All News Zelira Therapeutics Limited

Equities

ZLD

AU000000ZLD1

Market Closed - Australian S.E. Other stock markets 11:14:48 26/04/2024 am IST			5-day change	1st Jan Change
0.705 ^AUD	-0.70%		-0.70%	-21.67%

15/04	Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	MT
22/02	Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	15/04	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	22/02	CI
Zelira Therapeutics Secures Grant Funding for Cannabinoid Product	08/01	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	15/11
Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
Zelira Therapeutics Limited Announces Board Changes	31/23/31	CI
Transcript : Zelira Therapeutics Limited - Special Call	31/23/31
Zelira Therapeutics Bags Nearly AU$5 Million More Investment for HOPE SPV; Shares Rise 4%	22/23/22	MT
Zelira Therapeutics Limited announced that it expects to receive $22 million in funding	22/23/22	CI
Zelira Therapeutics Raises AU$1.8 Million Via Placement	15/23/15	MT
Zelira Therapeutics Halts Securities Trading Pending Capital Raising Announcement	13/23/13	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/23/28	CI
Transcript : Zelira Therapeutics Limited - Special Call	22/23/22
Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive Director	20/23/20	CI
Zelira Therapeutics Secures Nearly $9 Million Funding for US Clinical Trials of HOPE	15/23/15	MT
Zelira Therapeutics Secures R&D Tax Rebate	30/23/30	MT
Zelira Therapeutics Completes Drug Trial Patient Enrolment	21/22/21	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	17/22/17
Zelira Therapeutics Launches ZYRAYDI™ B2b Technology to Create Pharma-Grade Cannabis Capsules & Tablets for Global Markets	20/22/20	CI
Zelira Therapeutics Enrolls Two-Thirds of Patients for Diabetic Nerve Pain Medication	15/22/15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Zelira Therapeutics Limited

Equities

ZLD

AU000000ZLD1

All News

Filters